GTC Biotherapeutics

GTC On The Fast Track To $2M

WBJournal.com (Free subscription) | 10/06/2008

The U.S. Food and Drug Administration has accepted GTC Biotherapeutics Inc.'s biologics license application for review.

FDA Accepts ATryn(R) BLA Filing

Business Wire (Free subscription) | 10/06/2008

FRAMINGHAM, Mass.--(BUSINESS WIRE)--The US Food and Drug Administration, or FDA, has accepted for review GTC Biotherapeutics, Inc.’s ("GTC", Nasdaq: GTCB)

FDA Accepts ATryn(R) BLA Filing

The Earth Times Online Newspaper (Free subscription) | 10/06/2008

FRAMINGHAM, Mass. - The US Food and Drug Administration, or FDA, has accepted for review GTC Biotherapeutics, Inc.’s ( GTC , Nasdaq: GTCB) Biologics License Application, or BLA, for ATryn®. FDA

Ovation Pharmaceuticals's ATryn BLA Accepted for Review By FDA

Red Orbit (Free subscription) | 10/07/2008

Ovation Pharmaceuticals's ATryn BLA Accepted for Review By FDAPosted on: Tuesday, 7 October 2008, 09:00 CDT Ovation Pharmaceuticals, a biopharmaceutical company, has announced that the FDA has accepted for review the biologics license application for ATryn. Ovation acquired the exclusive US license to ATryn from GTC Biotherapeutics, allowing the company to develop and commercialize the product...

• FDA Accepts ATryn(R) BLA Filing - Business Wire
• FDA Accepts ATryn(R) BLA Filing - The Earth Times Online Newspaper
• See the 5 articles on the same subject

ATryn(R) (antithrombin alfa) BLA Filing Accepted by FDA

Business Wire (Free subscription) | 10/06/2008

DEERFIELD, Ill.--()--OVATION Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for ATryn® (antithrombin alfa). OVATION acquired the exclusive U.S. license to ATryn in August from GTC Biotherapeutics, allowing the company to develop and commercialize the product in this country. The acceptance...